Oric Pharmaceuticals
Brian Blank is an accomplished chemist with extensive experience in pharmaceutical research and development, currently serving as Principal Scientist at ORIC Pharmaceuticals Inc. since October 2018, where previous roles included Senior Scientist and Scientist. Prior experience includes a contracted Research Scientist position at ORIC Pharmaceuticals and a Scientist II role at REVOLUTION Medicines, where innovations included the design of small molecule inhibitors of protein tyrosine phosphatases. Notable academic contributions include a postdoctoral fellowship at the University of California, San Francisco, focusing on antimalarial compounds, and a Ph.D. in Chemistry from UCLA, where significant advancements in organocatalytic methods were achieved. Earlier work included synthesizing inhibitors for various enzymes during undergraduate studies at San Francisco State University, culminating in dual Bachelor's degrees in Chemistry and Biochemistry.
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.